argenx SE's stock fell by 3.85% and hit a 20-day low amid the announcement of the discontinuation of its Phase 3 UplighTED studies for efgartigimod due to futility concerns.
The decision to halt the trials was based on a recommendation from the Independent Data Monitoring Committee, which indicated that the studies were unlikely to meet their primary endpoints. This news has negatively impacted the company's market outlook and investor sentiment, leading to a decline in share price despite broader market strength, with the Nasdaq-100 up 0.78% and the S&P 500 up 0.58%.
The discontinuation of the trials raises concerns about the company's research progress in treating thyroid eye disease, although argenx emphasized its commitment to patient care and future research endeavors. The company plans to conduct a thorough analysis of the trial data to inform future studies.
Wall Street analysts forecast ARGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARGX is 1041 USD with a low forecast of 858.00 USD and a high forecast of 1264 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast ARGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARGX is 1041 USD with a low forecast of 858.00 USD and a high forecast of 1264 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 847.720
Low
858.00
Averages
1041
High
1264
Current: 847.720
Low
858.00
Averages
1041
High
1264
Wells Fargo
NULL
to
Overweight
maintain
2026-01-20
Reason
Wells Fargo
Price Target
AI Analysis
2026-01-20
maintain
NULL
to
Overweight
Reason
Wells Fargo raised the firm's price target on Argenx to $1,317 from $1,264 and keeps an Overweight rating on the shares. The firm raises its 2026-2030 Vyvgart estimates by 5%-15%, and highlights FY26 consensus estimate of $5.6B as too low given the growth trajectory. Wells estimates $6.5B assuming single-digit quarter-over-quarter growth in Q1 and low double-digit quarter-over-quarter growth Q2-Q4.
Morgan Stanley
Sean Laaman
Overweight
maintain
2026-01-08
Reason
Morgan Stanley
Sean Laaman
Price Target
2026-01-08
maintain
Overweight
Reason
Morgan Stanley analyst Sean Laaman raised the firm's price target on Argenx to $1,160 from $1,110 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARGX
Unlock Now
Truist
Danielle Brill
Buy
maintain
$950
2026-01-08
Reason
Truist
Danielle Brill
Price Target
$950
2026-01-08
maintain
Buy
Reason
Truist analyst Danielle Brill raised the firm's price target on Argenx to $1,030 from $950 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Citi
Samantha Semenkow
Buy
downgrade
2026-01-08
Reason
Citi
Samantha Semenkow
Price Target
2026-01-08
downgrade
Buy
Reason
Citi analyst Samantha Semenkow lowered the firm's price target on Argenx to $1,091 from $1,124 and keeps a Buy rating on the shares. The firm says its neurologist survey shows the Vyvgart launch continues to gain momentum. Citi says Argenx is a top pick for 2026. The target drop reflects a model update.
About ARGX
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
